Differential effects of Smad3 targeting in a murine model of chronic kidney disease

Physiological Reports

Volumn 1, Issue 7, 2013, Pages

  Kellenberger, Terese ^a   Krag, Søoren ^a   Danielsen, Carl Christian ^b   Wang, Xiao Fan ^c   Nyengaard, Jens Randel ^b   Pedersen, Lea ^a   Yang, Chuanxu ^b   Gao, Shan ^b   Wogensen, Lise ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Extracellular matrix; Fibrosis; Matrix metalloproteinase; Transforming growth factor 1

Indexed keywords

ALBUMIN; ALPHA TUBULIN; COLLAGEN; CREATININE; GELATIN; MATRIX METALLOPROTEINASE; SMAD3 PROTEIN; SMALL INTERFERING RNA; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; CREATININE URINE LEVEL; ELECTRON MICROSCOPY; ENDOTHELIUM CELL; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; HISTOLOGY; IMMUNOHISTOCHEMISTRY; KIDNEY BIOPSY; KIDNEY FIBROSIS; KIDNEY MASS; KIDNEY TUBULE BASEMENT MEMBRANE; MESANGIUM CELL; MICROALBUMINURIA; MOUSE; NONHUMAN; PHASE CONTRAST MICROSCOPY; REAL TIME POLYMERASE CHAIN REACTION; TRANSCRIPTION REGULATION; TRANSGENIC ORGANISM; UPREGULATION; WESTERN BLOTTING; ZYMOGRAPHY;

EID: 85008957400     PISSN: None     EISSN: 2051817X     Source Type: Journal    
DOI: 10.1002/phy2.181     Document Type: Article

References (50)

1. Akis, N., and M. P. Madaio. 2004. Isolation, culture, and characterization of endothelial cells from mouse glomeruli. Kidney Int. 65:2223-2227.
2. Ashcroft, G. S., X. Yang, A. B. Glick, M. Weinstein, J. L. Letterio, D. E. Mizel, et al. 1999. Mice lacking Smad3 show accelerated wound healing and an impaired local inflammatory response. Nat. Cell Biol. 1:260-266.
3. Danielsen, C. C., and T. T. Andreassen. 1988. Mechanical properties of rat tail tendon in relation to proximal-distal sampling position and age. J. Biomech. 21:207-212.
4. Danielsen, C. C., H. Wiggers, and H. R. Andersen. 1998. Increased amounts of collagenase and gelatinase in porcine myocardium following ischemia and reperfusion. J. Mol. Cell. Cardiol. 30:1431-1442.
5. Datto, M. B., J. P. Frederick, L. Pan, A. J. Borton, Y. Zhuang, and X. F. Wang. 1999. Targeted disruption of Smad3 reveals an essential role in transforming growth factor beta-mediated signal transduction. Mol. Cell. Biol. 19: 2495-2504.
6. Derynck, R., and Y. E. Zhang. 2003. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 425:577-584.
7. Derynck, R., Y. Zhang, and X. H. Feng. 1998. Smads: transcriptional activators of TGF-beta responses. Cell 95:737-740.
8. Fujimoto, M., Y. Maezawa, K. Yokote, K. Joh, K. Kobayashi, H. Kawamura, et al. 2003. Mice lacking Smad3 are protected against streptozotocin-induced diabetic glomerulopathy. Biochem. Biophys. Res. Commun. 305:1002-1007.
9. Gekle, M., P. Knaus, R. Nielsen, S. Mildenberger, R. Freudinger, V. Wohlfarth, et al. 2003. Transforming growth factor-beta1 reduces megalin-and cubilin-mediated endocytosis of albumin in proximal-tubule-derived opossum kidney cells. J. Physiol. 552:471-481.
10. Gharagozlian, S., K. Svennevig, H. J. Bangstad, J. O. Winberg, and S. O. Kolset. 2009. Matrix metalloproteinases in subjects with type 1 diabetes. BMC Clin. Pathol. 9:7.
11. Goumans, M. J., G. Valdimarsdottir, S. Itoh, F. Lebrin, J. Larsson, C. Mummery, et al. 2003. Activin receptor-like kinase (ALK)1 is an antagonistic mediator of lateral TGFbeta/ALK5 signaling. Mol. Cell 12:817-828.
12. Goumans, M. J., Z. Liu, and P. ten Dijke. 2009. TGF-beta signaling in vascular biology and dysfunction. Cell Res. 19:116-127.
13. Gundersen, H. J., T. B. Jensen, and R. Osterby. 1978. Distribution of membrane thickness determined by lineal analysis. J. Microsc. 113:27-43.
14. Hadler-Olsen, E., B. Fadnes, I. Sylte, L. Uhlin-Hansen, and J. O. Winberg. 2011. Regulation of matrix metalloproteinase activity in health and disease. FEBS J. 278:28-45.
15. Inazaki, K., Y. Kanamaru, Y. Kojima, N. Sueyoshi, K. Okumura, K. Kaneko, et al. 2004. Smad3 deficiency attenuates renal fibrosis, inflammation, and apoptosis after unilateral ureteral obstruction. Kidney Int. 66:597-604.
16. Kjeldsen, L., A. H. Johnsen, H. Sengelov, and N. Borregaard. 1993. Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J. Biol. Chem. 268:10425-10432.
17. Krag, S., J. R. Nyengaard, and L. Wogensen. 2007. Combined effects of moderately elevated blood glucose and locally produced TGF-{beta} 1 on glomerular morphology and renal collagen production. Nephrol. Dial. Transplant. 22:2485-2496.
18. Lehmann, R., and E. D. Schleicher. 2000. Molecular mechanism of diabetic nephropathy. Clin. Chim. Acta 297:135-144.
19. Lenz, O., S. J. Elliot, and W. G. Stetler-Stevenson. 2000. Matrix metalloproteinases in renal development and disease. J. Am. Soc. Nephrol. 11:574-581.
20. Locatelli, F., P. Pozzoni, and V. L. Del. 2004. Renal replacement therapy in patients with diabetes and end-stage renal disease. J. Am. Soc. Nephrol. 15(Suppl. 1): S25-S29.
21. Lu, Y., S. Liu, S. Zhang, G. Cai, H. Jiang, H. Su, et al. 2011. Tissue inhibitor of metalloproteinase-1 promotes NIH3T3 fibroblast proliferation by activating p-Akt and cell cycle progression. Mol. Cells 31:225-230.
22. Marshall, S. M. 2004. Recent advances in diabetic nephropathy. Postgrad. Med. J. 80:624-633.
23. Massague, J. 1996. TGFbeta signaling: receptors, transducers, and Mad proteins. Cell 85:947-950.
24. Meng, X. M., X. R. Huang, A. C. Chung, W. Qin, X. Shao, P. Igarashi, et al. 2010. Smad2 protects against TGF-beta/ Smad3-mediated renal fibrosis. J. Am. Soc. Nephrol. 21:1477-1487.
25. Miner, J. H. 1999. Renal basement membrane components. Kidney Int. 56:2016-2024.
26. Miner, J. H. 2012. The glomerular basement membrane. Exp. Cell Res. 318:973-978.
27. Nath, K. A., A. J. Croatt, G. M. Warner, and J. P. Grande. 2011. Genetic deficiency of Smad3 protects against murine ischemic acute kidney injury. Am. J. Physiol. Renal Physiol. 301:F436-F442.
28. Neuman, R. E., and M. A. Logan. 1950. The determination of hydroxyproline. J. Biol. Chem. 184:299-306.
29. Nyengaard, J. R., K. Chang, S. Berhorst, K. M. Reiser, J. R. Williamson, and R. G. Tilton. 1997. Discordant effects of guanidines on renal structure and function and on regional vascular dysfunction and collagen changes in diabetic rats. Diabetes 46:94-106.
30. Reeves, W., J. P. Caulfield, and M. G. Farquhar. 1978. Differentiation of epithelial foot processes and filtration slits: sequential appearance of occluding junctions, epithelial polyanion, and slit membranes in developing glomeruli. Lab. Invest. 39:90-100.
31. Roberts, A. B., A. Russo, A. Felici, and K. C. Flanders. 2003. Smad3: a key player in pathogenetic mechanisms dependent on TGF-beta. Ann. N. Y. Acad. Sci. 995:1-10.
32. Ronco, P., B. Lelongt, R. Piedagnel, and C. Chatziantoniou. 2007. Matrix metalloproteinases in kidney disease progression and repair: a case of flipping the coin. Semin. Nephrol. 27:352-362.
33. Sato, M., Y. Muragaki, S. Saika, A. B. Roberts, and A. Ooshima. 2003. Targeted disruption of TGF-beta1/Smad3 signaling protects against renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction. J. Clin. Invest. 112:1486-1494.
34. Tan, R. J., and Y. Liu. 2012. Matrix metalloproteinases in kidney homeostasis and diseases. Am. J. Physiol. Renal Physiol. 302:F1351-F1361.
35. Thrailkill, K. M., B. R. Clay, and J. L. Fowlkes. 2009. Matrix metalloproteinases: their potential role in the pathogenesis of diabetic nephropathy. Endocrine 35:1-10.
36. Tojo, M., Y. Hamashima, A. Hanyu, T. Kajimoto, M. Saitoh, K. Miyazono, et al. 2005. The ALK-5 inhibitor A-83-01 inhibits Smad signaling and epithelial-to-mesenchymal transition by transforming growth factor-beta. Cancer Sci. 96:791-800.
37. Wang, A., F. N. Ziyadeh, E. Y. Lee, P. E. Pyagay, S. H. Sung, S. A. Sheardown, et al. 2007. Interference with TGF-beta signaling by Smad3-knockout in mice limits diabetic glomerulosclerosis without affecting albuminuria. Am. J. Physiol. Renal Physiol. 293:F1657-F1665.
38. Wang, X., Y. Zhou, R. Tan, M. Xiong, W. He, L. Fang, et al. 2010. Mice lacking the matrix metalloproteinase-9 gene reduce renal interstitial fibrosis in obstructive nephropathy. Am. J. Physiol. Renal Physiol. 299:F973-F982.
39. Warner, G. M., J. Cheng, B. E. Knudsen, C. E. Gray, A. Deibel, J. E. Juskewitch, et al. 2012. Genetic deficiency of Smad3 protects the kidneys from atrophy and interstitial fibrosis in 2K1C hypertension. Am. J. Physiol. Renal Physiol. 302:F1455-F1464.
40. Welsh, G. I., and M. A. Saleem. 2012. The podocyte cytoskeleton-key to a functioning glomerulus in health and disease. Nat. Rev. Nephrol. 8:14-21.
41. Williams, J. M., J. Zhang, P. North, S. Lacy, M. Yakes, A. Dahly-Vernon, et al. 2011. Evaluation of metalloprotease inhibitors on hypertension and diabetic nephropathy. Am. J. Physiol. Renal Physiol. 300:F983-F998.
42. Wogensen, L., C. B. Nielsen, P. Hjorth, and L. M. Rasmussen, A. Hoj Nielsen, K. Gross. 1999. Under control of the Renin-1c promoter, Locally, produced transforming growth factor-yS1 induces accumulation of glomerular extracellular matrix in transgenic mice. Diabetes 48: 182-192.
43. Wu, D. T., M. Bitzer, W. Ju, P. Mundel, and E. P. Bottinger. 2005. TGF-beta concentration specifies differential signaling profiles of growth arrest/differentiation and apoptosis in podocytes. J. Am. Soc. Nephrol. 16:3211-3221.
44. Wynn, T. A. 2008. Cellular and molecular mechanisms of fibrosis. J. Pathol. 214:199-210.
45. Yagi, K., D. Goto, T. Hamamoto, S. Takenoshita, M. Kato, and K. Miyazono. 1999. Alternatively spliced variant of Smad2 lacking exon 3. Comparison with wild-type Smad2 and Smad3. J. Biol. Chem. 274:703-709.
46. Yamamoto, T., T. Nakamura, N. A. Noble, E. Ruoslahti, and W. A. Border. 1993. Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. Proc. Natl Acad. Sci. USA 90:1814-1818.
47. Yang, X., J. J. Letterio, R. J. Lechleider, L. Chen, R. Hayman, H. Gu, et al. 1999. Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-beta. EMBO J. 18:1280-1291.
48. Zeisberg, M., M. B. Ericksen, Y. Hamano, E. G. Neilson, F. Ziyadeh, and R. Kalluri. 2002. Differential expression of type IV collagen isoforms in rat glomerular endothelial and mesangial cells. Biochem. Biophys. Res. Commun. 295:401-407.
49. Zhou, L., P. Fu, X. R. Huang, F. Liu, A. C. Chung, K. N. Lai, et al. 2010. Mechanism of chronic aristolochic acid nephropathy: role of Smad3. Am. J. Physiol. Renal Physiol. 298:F1006-F1017.
50. Zhu, Y., J. A. Richardson, L. F. Parada, and J. M. Graff. 1998. Smad3 mutant mice develop metastatic colorectal cancer. Cell 94:703-714.